Dr. Reddy's Laboratories announces the launch of AVIGAN® (Favipiravir) in India

News Desk, News Nation 360: Dr Reddy’s Laboratories Ltd. announced the launch of AVIGAN® (Favipiravir) 200 mg Tablets in India. The launch is part of the global licensing agreement with FUJIFILM Toyama Chemical Co. Ltd. that grants Dr Reddy’s exclusive rights to manufacture, sell and distribute AVIGAN (Favipiravir) 200 mg Tablets in India. AVIGAN® (Favipiravir) has been approved by the Drugs Controller General of India (DCGI) for the treatment of patients with mild to moderate COVID-19 disease. Dr Reddy’s AVIGAN® comes in a complete therapy pack of 122 tablets with a two-year shelf life. M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets),  Dr Reddy’s  Laboratories,  told  they are pleased to bring this

important innovator medicine to the patients in India. The need for high quality and efficacy, affordability and better disease management are key priorities for them. They believe that AVIGAN® would provide an effective treatment option to the COVID-19 impacted patients in India. To ensure accelerated access to the medicine, Dr Reddy’s has initiated a free home delivery service in 42 cities in the country, and a Helpline Center at 1800-267-0810 / www.readytofightcovid.in between 9 a.m. to 9 p.m. IST, Monday through Saturday. 

Report : Anustup Kundu

  • Facebook
  • Twitter
  • Instagram